

# Annual Report

2021

**JDRF** IMPROVING  
LIVES.  
CURING  
TYPE 1  
DIABETES.



## A message from our Chairman, Richard Goyder AO

**2020/2021 remained a challenging time as Australia worked through isolation and lockdowns and the ensuing economic and emotional toll that accompanied COVID-19. Thankfully the green shoots delivered by vaccines and treatments have begun to chart a path to the future.**

The swift progress in COVID-19 vaccine development and rollout reinforces a belief central to our work at JDRF – that progress in pursuit of even the greatest scientific challenges can be made swiftly when energy, commitment and knowledge are joined together.

Delivery in challenging times has been at the core of our work at JDRF this year. We know that while the world was understandably focused on a pandemic, type 1 diabetes (T1D) was not receding. The impact and challenges faced by the more than 125,000 Australians living with T1D, and the eight more diagnosed every day, didn't change. Our report *The Economic Cost of T1D* showed that the disease costs Australia almost \$3 billion a year. This figure is staggering and generates a heavy burden for many. We hear stories of young families having to choose between lifesaving technology that costs thousands of dollars and saving for a home or having another child. We owe it to our community to end this inequity in treatment access while we pursue a cure.

The fact that JDRF has been able to maintain our focus and make meaningful inroads towards delivering on our vision of a world without T1D is nothing short of remarkable.

I commend and congratulate our researchers, volunteers, partners, donors, and staff for banding together to ensure our mission was not derailed. In fact, over the last 2 years, we've contracted to provide over \$30 million in new and progressing research.

Over the pages of this report, you will see some of this progress. We have worked hard to gain a deeper understanding of the lived experiences and financial impact of T1D. Recognising the importance of connection and community, we came together virtually for the Type One Summit, Australia's largest event focused on living with T1D. Despite the extreme challenges the city of Melbourne has experienced, the BANDIT clinical trial team based at St. Vincent's produced some potentially game-changing results. All of this could not be achieved without financial backing and this year we saw continued support from large businesses and individual Australians alike, through the funding of the new Centre of Excellence in Perth and our second ever Giving Day raising a staggering two million dollars.

To all of you who have been part of these achievements, our heartfelt thanks. We are as passionate as ever about creating a world without type 1 diabetes and look forward to your continued support to make it a reality.

Richard Goyder AO  
Chairman, JDRF Australia

# A message from our CEO, Mike Wilson OAM



**As Australia and the world adjusts to the ever-changing scenarios brought on by COVID-19, JDRF is no different. As you will see over the pages of this report, we have continued to innovate and adapt to deliver on our mission to improve lives today and tomorrow by accelerating life-changing breakthroughs to cure, prevent and treat type 1 diabetes and its complications. Most importantly, we owe it to the T1D community to look forward, to think about what is next, and how we can shape this future positively.**

To that end, this report looks at our progress in the financial year 2020/2021 but also provides a window into our plans for the future. One important milestone we marked this year was 100 years since the discovery of insulin, a lifesaving treatment for millions of people around the world. However, as an organisation and a community we recognise that we cannot and will not wait another century to rid the world of this disease entirely.

Key to achieving this is being innovative in our approach and delivery. While COVID-19 has changed the operating environment irrevocably, our focus on progress, agility and creating a collective voice for the T1D community has remained constant and will continue as we pursue our agenda in the coming years.

One key example of JDRF's ability to provide a platform for this collective voice is through our advocacy program.

JDRF Australia has a strong and proud record in bringing the issues of the T1D community to Government, and with a pending Federal Election in 2022 we will continue to do so. Our #AccessForAll campaign seeks to level the playing field when it comes to technology access for the T1D community. Access is not about having the latest, fastest or smallest device – for people living with T1D it is lifesaving and life-changing. Our campaign shows how an investment of \$100m per year can make a significant difference to the lives of those in the T1D community. This vibrant, passionate, strong community is why we do what we do and we will continue to advocate, increase influence and deliver greater investment to support the more than 125,000 Australians living with T1D.

We hope you take from this report that JDRF is an organisation with impact at its centre – and that impact extends from research and advocacy, through to community engagement, awareness raising and fundraising to drive it all.

Our work couldn't be delivered without your continued support and I thank all of our supporters, board members, staff and volunteers who have made this year a success and will continue to power our mission in the years ahead. We're here until T1D isn't.

Mike Wilson OAM  
CEO and Managing Director, JDRF Australia

# The Power of Advocacy



## A message from Rowan Ramsey MP

I was fairly unaware of the diabetes challenge facing Australia and the role of the JDRF until my niece was diagnosed with T1 and I joined the Parliamentary Friendship Group about twelve years ago. I do not remember which event came first but perhaps it's an ill wind that blows no good, because my niece who was about to commence her Bachelor of Nursing at the time was able to use her new personal challenge to write a number of her assignments on diabetes. Subsequently she worked as a diabetes nurse both in Australia and the UK and now is back in Adelaide working as a diabetes educator.

Having joined the Parliamentary Friendship Group, I was subsequently asked to become a Co-Chair following Ken Wyatt's promotion to the Ministry in 2015, a position I have been extremely pleased to hold since.

It was through my involvement in the group I became much more aware of the impact of diabetes on individuals, their families and the nation and the vitally important role the JDRF plays in lobbying for better support for the T1 sector. They bring their issues to the Parliament in a very powerful way. The "Kids In The House" programs have been one of the most effective lobbying tools I have seen in my time in politics. The program subsequently draws elected representatives to participate in the other promotion activities where we meet with the wider diabetes community and learn more about the challenge of diabetes.

The effectiveness of the JDRF education process cannot be questioned with significant investment coming from the Australian Government both in support for devices, services and heavy investment in clinical trials.

While there is much more to do, we and the JDRF should not rest until we have a cure. However, we have come a very long way in lifting public awareness of the impacts of diabetes and the level of support provided for those who deal with the daily battle.

Well done to the JDRF!



Federal Member for Grey  
Co-Chair - The Parliamentary Enemies of Diabetes



## A message from Graham Perrett MP

I first recall meeting JDRF and my local advocate soon after I was first elected back in 2007. A large group of JDRF advocates and their parents descended on Parliament House as part of their Kids In The House campaign. I'll never forget the impact that human wall of blue had and the stories we were told about the challenges of living with T1D. The advocates brought with them not only passion and drive in telling their story, but also supported their argument with facts and research. This is a powerful combination!

This is one of the things that makes JDRF stand out. As an organisation, they understand the power of human stories and advocacy but the need to be grounded in data and facts. It makes it much easier to advocate for a change, be it access or research funding, if we can see the impact our support can have. And JDRF deliver that in spades.

Type 1 diabetes is a challenging condition to live with and hearing local voices from all over the country while we are down in Canberra is a refreshing difference to professional lobbyists. We have actually met and spoken to the people who are impacted and those examples of life with type 1 really stay with you.

I support JDRF's mission as realistic changes from government can both change (and save) lives – how could a fair dinkum politician not be on board with JDRF!

A handwritten signature in black ink that reads "Graham Perrett". The signature is written in a cursive, slightly slanted style.

Mr Graham Perrett MP  
Member for Moreton, Queensland


# Managing the cost of T1D in Australia

As the leading global organisation representing the T1D community, JDRF strives to deliver an understanding of the challenges of living with T1D to help deliver change for our community. This year we conducted two significant pieces of research to arm us with the economic facts and the lived experience of T1D in Australia.

First, we partnered with Lonergan Research to get insight from more than 1,000 Australians living with T1D about the mental impact and financial toll of the condition on social, professional and personal life.

Second, it had been more than a decade since the last large-scale study of the economic impact of T1D in Australia was undertaken. Recognising the need for a true understanding of the economics of T1D to help shape appropriate solutions, we sought to tackle that gap with a detailed report that underlined the challenges but also paved the way for solutions. The landmark *Economic Cost of Type 1 Diabetes* report in 2020 mapped out the financial, social and societal implications of type 1 diabetes and the results were startling.

To view the report, please visit [jdrf.org.au/100years/the-cost-of-t1d/](https://jdrf.org.au/100years/the-cost-of-t1d/)



## Key findings:

- There are 127,000 people living with T1D in Australia and that number is growing by eight more people every day.
- The economic cost of T1D is now a staggering \$2.9 billion per year.
- Complications of T1D have a huge impact on the costs - having two complications increases the cost to the economy by more than four times.
- Access to life-saving technologies and new treatments can reduce costs and bring mental health benefits.

---

## Incidence of Type 1

The report showed that there are more than 127,000 Australians living with T1D and that number is growing rapidly. 3,000 new cases are diagnosed every year and we know there are 25,000 individuals in the early stages of T1D who haven't been diagnosed yet.

---

## The cost to our economy

People living with T1D cost the economy \$2.9 billion annually, placing a heavy burden on the taxpayer:

- Direct costs, for example hospitalisation or unemployment benefits, are estimated at \$1 billion annually, accounting for 36% of total annual costs.
- We also measured the more insidious indirect costs - things like the cost of unemployment, absenteeism and impact on wellbeing. These costs amount to an eye-watering \$1.9 billion annually.

And while T1D incurs great cost for the Federal and State governments, there is also the expenditure at individual level on hospital treatment, technology and many associated costs.

Our research shows that on average, Australians reported an out-of-pocket cost of \$4,777 per year to cover health insurance, medical appointments and monitoring equipment.

---

## The cost of complications

One of our major findings was that diabetes complications exponentially add to the cost of T1D.

- The 40% of people with type 1 diabetes who experience complications from the disease, like neuropathy, account for the majority (75%) of the annual cost.
- 26% of people with T1D have two or more complications. On average, the cost of having 2 or 3 complications is estimated to be \$38,000 and \$49,000 respectively.
- Hospitalisation due to diabetes related problems and hypoglycaemic emergencies account for 2% of total annual costs.

- Financial burden is exacerbating mental health issues for Australians living with T1D, with our research showing half of those surveyed for our Challenges of T1D report (50%) experience feelings of depression and almost 9 out of 10 (87%) revealing their condition negatively impacts their quality of life.

---

## The cost to mental health

What we found out about the mental health costs for people with type 1 and their families through our research did not come as a surprise either:

- People with T1D are five times more likely to suffer from depression and 1.8 times more likely to suffer anxiety due to considerable lifestyle changes to manage T1D, constant worry and feelings of hopelessness due to additional complications.
- T1D finds its way into every part of life. Our report found the impact on spontaneous activities was so large that T1D impacted people's romantic relationships (40%) and career choices (33%).
- Approximately 1 in 5 parents of children with T1D experience significant psychological distress, including depression and anxiety, as a result of managing their child's condition. This mirrors information we are seeing in our peer support programs and closed groups, that aim to support people with the mental and social challenges of T1D. We have seen a 162% growth in our online support groups for parents this year.

### This report shows the need for lifesaving technology

Given diabetes complications are so costly, it makes sense to harness the technology that helps avoid long-term problems.

Researchers have shown that access to continuous glucose monitoring devices (CGMs) and insulin pumps can help individuals have a tighter control of their glucose levels, reducing the risk of ongoing complications and the significant cost that results.

# Our election ask

In the lead up to the 2022 Federal Election, JDRF Australia is mobilising the Australian T1D community to persuade all sides of politics to commit to providing increased access to technologies as a basic standard of care for the more than 125,000 Australians living with T1D, and to ensure that their access is not determined by birthdate or bank balance, but by professional advice and personal preference.

Lifesaving and life-changing technologies to measure blood glucose and deliver insulin in response to need are the foundation of treatment and care for type 1 diabetes (T1D) in the 21st century.

Given this, all Australians living with T1D should have equitable access to the most effective diabetes management system suitable to their clinical circumstances.

However, in Australia today access to these technologies is inconsistent, inequitable, and incomplete. Important government initiatives improve access for some groups but not all, and thus diabetes management technologies are underutilised. Even worse, access cuts out for many when they reach adulthood.

**" ...When I think about the technology that is currently available but inaccessible to so many, it's difficult to think not only of the times when I was growing up that such technology could have prevented me from serious incidents but would also have prevented the complications I have to deal with now at the relatively young age of 32."**

**– Daniel, 32**

This needs to change. JDRF's #AccessForAll campaign aims to make type 1 diabetes technology affordable and accessible for everyone who wants it and could benefit from it. This means increasing coverage of insulin pumps (tubed and patch) and glucose monitors (CGM and Flash GM).

It is not acceptable, equitable or justifiable that access to these devices is dictated by age or wealth rather than need and benefit, or that the pathway for accessing innovative new treatments is complex, challenging, expensive, and time-consuming.

The first step to correcting these issues is expanding access to diabetes technologies to all those who need it, requiring an investment of \$100m per year to:

- 1 Support expanded access to CGMs and Flash GMs for adults who currently miss out.**
- 2 Expand access to insulin pumps to people of all ages with a low-income healthcare card.**
- 3 Review the reimbursement framework (of Prostheses List and National Diabetes Services Scheme) so that it is fit for purpose, enabling the swift and transparent assessment of future technologies for reimbursement.**

A critical element included in this investment is \$7.5m per year to allow continued access to subsidised CGMs and pumps for those who already have access to them and would otherwise have this access taken away at their 18th or 21st birthday, which is a travesty.

A close-up photograph of a person's arm wearing a small, light-colored patch pump. The person is wearing a grey t-shirt. The background is blurred, suggesting an outdoor setting.

**“The pump system I currently use is... a patch pump, therefore has no tubing, it has a locked phone to control the settings and daily insulin management, it is 100% waterproof, it is small and discreet, and it is easy to use.**

**This pump has only been introduced to the Australian market; it is not funded under NDSS. If it was funded by NDSS, I and a lot of other people living with T1D would be able to benefit from this technology. Access to this pump has made my life and my family’s lives much more normal.”**

**– Liam, age 8, patch pump user**



**“Flash glucose monitors (FGM) can prevent this nightly ritual of worry. I have been using Flash for the past few years, and as a young independent adult it has been a game changer. I work for myself, love to go on beach walks and enjoy travelling by myself. Having access to a FGM allows me the freedom to work and experience the world, without the constant worry of my blood sugars.**

**Unfortunately, when I turned 21, my FGM was no longer freely accessible to me. My current situation means I can’t always afford my FGM. ”**

**– Shanna, FGM user**

# Maintaining our community connection in a COVID world

At its core JDRF is a community driven organisation passionate about bringing the lived experience of T1D into the spotlight and providing a platform to the T1D community to connect, collaborate and exchange ideas. Over the last 12 months, while the challenge of delivering this connection has become more difficult, never has it been more important.

To provide that connected experience we took our largest community event, Type One Summit, online. Type One Summit is Australia's leading event designed solely for people living with T1D and their carers. It provides them with a forum to share stories, learn from experts about the latest advances in research along with tips and tricks to help manage T1D.

This year's Summit provided educational content, addressing common challenges and needs for a range of ages and life stages in the T1D community. The new, virtual format meant we could offer sessions from both international and local experts.

Further, those in regional and remote areas had the opportunity to find out more from our technology partners, T1D clinicians and researchers, and hear stories from other members of the T1D community dealing with similar challenges.

JDRF remains committed to developing new and innovative ways to create a connected community and providing them with the support and guidance they need at various stages of their journey. As the primary group advocating for the more than 127,000 Australians living with T1D and their families these events are a vital part of delivering our mission.



## Some feedback from our attendees:

“Absolutely needed to hear this information from people rather than reading about it. Living in a regional area our access to these events are limited so gathering what the experts are researching on T1D is invaluable!! Thanks for hosting a crucial event!”

“It was my first JDRF event and I found it was extremely well run and informative. Congratulations to everyone who put today together. Thank you!”

“I’ve had diabetes for over 20 years. For me, the most valuable sessions are not how extreme you can be with diabetes, although these are good to hear, but hearing from a variety of people about how they are managing their diabetes, good and bad.”

“It was wonderful to be able to attend today’s event. Great support for parents in remote areas also for adult type 1s it was easier/cheaper than travelling to venue. I found it valuable, informative and inspirational, as support is lacking for type 1s.”

## The event was a great success with:

**1,361**

registrations

**88**

minutes as the average visit time

**99%**

would attend another virtual summit

**95%**

rated the event very good/excellent

**100%**

would recommend the summit to a friend or relative

# Research milestones

We know research holds the key to creating a world without T1D. Through effective advocacy, generous support and prudent governance, we have been able to ensure our research has not been impacted by the economic challenges of the last 12 months. Thanks to you, our supporters, we have been able to continue funding promising areas of research and uncover exciting new pathways to treat and potentially cure this lifelong condition.

**All of our research is a step towards our ultimate goal of a cure that delivers a world without T1D**

## **Our approach to research into T1D is centred on ensuring:**

- Every person at risk of T1D is identified and provided with appropriate support
- People across all stages of T1D have access to high quality clinical trials, including clinical trials of therapies that can potentially delay or reverse T1D
- Australian-based innovative discoveries are translated into novel therapies
- Improving lives for people with T1D through better technology and treatments

These, and other exciting innovations such as precision medicine, present great hopes in halting the progress of T1D and some of the best research is happening in Australia, including:

### **BANDIT: World-first clinical trial available to Australians, potentially delaying the onset of T1D**

This trial, led by renowned researcher Professor Tom Kay, has the potential to fundamentally change how we tackle T1D. It involves repurposing a treatment for another condition and is showing promise in slowing the destruction of insulin producing cells in the pancreas. This trial will help develop a greater understanding of how the treatment (baricitinib) works and could lead to new options to slow the onset of T1D.

### **General Population Screening: Tackling T1D before it takes hold**

Led by Dr Kirstine Bell, our Type 1 Diabetes National Screening Program will begin with a pilot study in 2022. Children are often diagnosed with T1D late with approximately 1 in 3 children ending up in intensive care with life-threatening complications. Being able to detect the disease early is essential to avoid these complications and helps us target new innovative treatments (such as the work Professor Kay is doing with BANDIT) to those that need them most.

---

## Hybrid closed-loop trials: Using technology to act like a pancreas

A hybrid closed-loop system is best described as something that can act almost like an artificial pancreas, monitoring blood glucose and delivering insulin when it's needed. A clinical trial led by Professor David O'Neal found that time in range increased 15% using the system. Importantly, hybrid closed-loop users scored better on measures of diabetes-specific positive wellbeing and quality of life, paving the way for increased use of this ground-breaking technology. This trial was funded by JDRF Australia through the Type 1 Diabetes Clinical Research Network, an initiative delivered as a result of JDRF's advocacy efforts.

---

## New Science Accelerator grants: Supporting the next generation of researchers

In July 2021 JDRF and The Leona M. and Harry B. Helmsley Charitable Trust announced more than \$1.2 million in new funding for three outstanding early-mid career Australian researchers. Awarded as part of an ongoing partnership with the Trust, the awards will support the recipients in becoming research leaders, ensuring T1D research can retain its brightest prospects. Importantly, the grants will support researchers currently working with samples taken during ENDIA, another JDRF funded study, showing the importance of connection and continuity in research.

---

## JDRF Global Centre of Excellence in Diabetes Research: Improving the lives of children with T1D

JDRF Centres of Excellence represent a new research model, bringing together experts from diverse fields and multiple institutions to accelerate the pace of T1D research. Based at the Children's Diabetes Centre, Perth, the JDRF Global Centre of Excellence is one of only four Centres in the world, and the first outside the US. The centre is focusing on developing personalised models of T1D care, fast-tracking translation of research as well as bringing together experts from diverse fields to accelerate T1D breakthroughs. The Centre of Excellence was made possible through generous support from the Telethon Trust and Rio Tinto.

---

## Professor Toby Coates: A game changing new method of islet transplantation

Islet transplantation is a life-changing treatment for people with severe T1D. The current method involves transplanting islet cells into the liver, but this can be invasive, difficult to monitor, and requires a large number of cells for success.

Prof Coates has developed a new method of islet transplantation under the skin, using an artificial skin graft originally approved for use in burns patients. This graft provides the transplanted cells with their own blood supply, making them much more likely to survive after transplantation.

This highly innovative approach is now being trialled in people with type 1 diabetes for the first time. If successful, it could be a game changing new approach for islet transplantation – able to be performed under local anaesthesia, easy to monitor or remove, and significantly less expensive.

For more information on our research, visit [jdrf.org.au/research](http://jdrf.org.au/research)



# Fundraising

Central to our ability as an organisation to represent, support and advocate for everyone living with T1D, as well as deliver world-class research, is our ability to fund these programmes and research. Our type 1 community is passionate, committed, and gives back in so many ways. Their ability to persevere in challenging circumstances is remarkable. We saw this spirit throughout 2020/21 as despite the challenging economic headwinds, the community banded together to deliver a massive \$8.5 million to our fundraising activities, so that we can keep on fighting to defeat T1D.

We know it takes a whole of community approach to tackle a challenge like T1D. That's why alongside our generous supporters, walking, cycling (or hair-dying!) to support our work, we're also indebted to the philanthropists, charitable trusts and corporates who got behind our mission. Our belief is that through partnership, prudence and good governance, such large scale support can be leveraged to deliver an even greater outcome. Evidence of this has been through our work with The Helmsley Charitable Trust, the Type 1 Diabetes Clinical Research Network and our second ever Giving Day, which raised \$2m. Leveraged funding is a key platform to our approach, and every dollar we bring in from our generous fundraisers is more than doubled through leveraged government and partner support.

---

## One Walk

Most of Australia was out of lockdown in October 2020 and it felt like the whole country was ready to walk. JDRF's flagship event totally surpassed our expectations and bridged the shortfall from when many of our community events were impacted by COVID-19.

Over 5,000 people donned their Blue Army gear and joined the movement to defeat type 1 diabetes, raising more than \$1.2 million. Participants walked 120,000 steps to recognise the number of people living with the condition and rallied virtually to march towards a future free of type 1 diabetes.

---

## One Ride

Our community got on their bikes in September and rode their way to over \$110,000 in donations. For the first time in 15 years of racing, the event moved from the Barossa Valley to online. And in the virtual world, the competition was just as fierce to make a difference to the lives of people living with T1D.

---

## Officeworks Round Up to Make a Difference

We partnered with Officeworks in June and July 2020 for their Round Up to Make a Difference campaign. Customers could round up their purchases to the nearest dollar across 12 Melbourne stores, with the difference being donated to JDRF. This initiative raised close to \$80,000 in just a few weeks.

The campaign was close to the heart of Officeworks, with CFO Michael Howard living with T1D since he was 11.

---

## Giving Day

In June 2021 our generous community had their donations matched by our loyal philanthropists and corporate partners in our annual Giving Day. Every donation made as part of the campaign was doubled and had twice the impact. Together, our dedicated donors raised over \$2 million, an incredible sum to fund the most promising work of researchers into T1D.





## Why I support JDRF

**JDRF's mission was one that resonated with me before I joined the board in 2015, as I have two T1D children, diagnosed 30 years apart..**

My involvement with JDRF, coupled with my children's experience, has put me in a unique position to see the real impact an organisation like JDRF can have. Over these 30 years, we have seen technological advances such as the closed loop system but have also seen Australia have a global impact through continued research and innovation. In my time involved with JDRF we have seen three rounds of the Type 1 Diabetes Clinical Research Network (T1DCRN) come to life – supporting researchers who have the potential to fundamentally change the lived experience for people like my children and thousands of others. JDRF has driven change around how T1D is understood and supported by Government and provided support and education to thousands of families.

How has JDRF done this?

Firstly, it has an outstanding Board and Executive Team and as an organisation is extremely well focused on raising and applying funds in an efficient and measurable manner. Importantly, the organisation has the right balance between funding research for a cure and making lives better for those with T1D. JDRF is recognised as a world-leading contributor to the cause of curing T1D and assisting those in the T1D community to live healthier and longer lives and is a shining example of Australia punching well above its weight.

Secondly, as an organisation, it has continued to evolve. The realisation and continued development of JDRF's vision of a Board and an Advisory Board of highly qualified and committed professionals and a modern, efficient structure has positioned JDRF as a pre-eminent NFP in Australia.

This has been brought to life through the creation of a highly-skilled, nimble and evolving organisation that continues to improve and challenge how things can be done best. For instance, the translational program is a critical, relatively new initiative to accelerate high impact research towards translation and commercialisation, and the establishment of the Centre of Excellence in Perth is an example of JDRF seizing a brilliant, world-leading opportunity and executing on it.

COVID-19 has challenged every business, from global multinational to local retail, and the NFP sector is no different. JDRF has responded to COVID-19 challenges extremely well, posting a strong financial result without compromise to its mission and introduced key new initiatives like Giving Day. Virtual treatments of events like the JDRF One Ride demonstrates the agility and creative thinking in the organisation and its ability to adapt well in a very challenging year.

I have been privileged to be a small part of JDRF. To be able to observe at closer quarters, the difference made to the lives of all those living with type 1 diabetes in Australia and the huge, sustained effort that has gone in to funding important research for a cure, has been inspiring, heart-warming and important to me.

I strongly encourage anyone who is looking to support an organisation with impact at its core, to consider JDRF.

**Jeff Browne is chairman of ASX-listed MA Financial Group as well as automotive business Walkinshaw Automotive Group and the former chairman of ASX-listed carsales.com. He is also the former Managing Director of the Nine Network.**



# Year in Numbers



**\$14.5M**

Invested in research



**>\$30M**

Contracted research for ongoing programs



**50**

Studies and clinical trials funded



**2,600+**

People involved in clinical trials



**49,000**

Number of people informed about clinical trials and updates



**461,360**

Needles avoided via the insulin pump program



1,157

KIDSAC newly diagnosed support pack deliveries



23m+

Impressions generated through our 2021 Giving Day campaign



7,670

New supporters



3,225

New members to support groups



1,125

Peer support phone calls



523

Times Straight To The Point support guide was requested



103

MP meetings in-person or virtually to advocate for T1D

# 2020/2021 financial results

**Our financial position reflects both delivery of mission in a challenging economic environment, while also remaining prudent and prepared for an uncertain climate.**


The challenges of 2019/20 carried over to 2020/2021 with large parts of the country managing lockdowns and the associated economic fallout. Community fundraising was heavily impacted by stay-at-home orders. Despite this, underlying revenue remained parallel to last year, with growth delivered through a generous donation for the JDRF Global Centre of Excellence in WA.

The move to running virtual events and a matched Giving Day alongside the development of innovative digital marketing approaches allowed us to reduce our fundraising expenses by 56%. This prudent approach together with the receipt of a multi-year directed donation has supported the delivery of a surplus that was more than double the previous financial year. This surplus will be acquitted to contracted research payments in FY22.




## Mission Delivery

While we were able to continue to deliver all of our community programs, COVID-19 has also impacted and delayed some elements of our research programs and as a result \$6M of contracted research milestone payments were delayed and will be completed and paid in FY22. In the absence of these delays mission delivery would have been in line with FY19. All programs are continuing to progress and catch up with more than \$30M new research having been contracted in FY20/21.




## Contracted Research

Research contracted during FY20 and FY21 was not slowed down by COVID-19. In fact, the renewal and growth of partnership and government funding has added momentum to the portfolio. We have an exciting pipeline of ground breaking research that both ensures progression in our portfolio and accelerates our agenda of innovation to improve lives and ultimately cure type 1 diabetes.




## Fundraising Revenue

While community fundraising was impacted heavily by stay-at-home orders the first fully virtual JDRF One Walk Step Challenge was strongly supported and achieved a result equivalent to FY19. This coupled with the success of our second Giving Day, backed by a strong matching pool from our generous philanthropic community and other partners, ensured that our core revenue remained stable with growth coming from the donation for the WA Global Centre of Excellence.



## Fundraising Efficiency

The necessary move away from physical events, Gala Balls and Walks, together with the development of innovative digital marketing capability and ongoing prudent management of costs, has improved the fundraising efficiency of JDRF significantly. This has ensured that through difficult times 96.5% of fundraising revenue was available for contribution to mission. This result reflects the unique circumstances that JDRF's business response to COVID delivered. It is expected that as Australia normalises and in-person events become possible some investment in the core fundraising business will be required, balanced by consolidation of the efficiencies delivered.



# JDRF Board of Directors

## **Richard Goyder AO | Chair**

Co-Chair of the Advisory Board  
Appointed 2016  
BCom, FAICD

Chairman, Qantas Airways; Woodside Petroleum Limited; Australian Football League Commission; West Australian Symphony Orchestra, and Channel 7 Telethon Trust; Former Managing Director, Wesfarmers; Honorary member of the Business Council of Australia; Father of a son with type 1 diabetes

## **Paul Heath | Vice-Chair**

Member of the Board and Investment Committee, JDRF International  
Appointed 2012  
B.Com., SFFin.

CEO and Executive Director, Koda Capital; Director, JDRF International; Member, Endowment Investment Committee of the Benevolent Society; Former CEO, JBWere Pty Ltd; Father of a daughter with type 1 diabetes

## **Stuart Green | Treasurer**

Chair of the Finance & Audit Committee  
Appointed 2010 (Resigned 19 November 2020)  
B.A. (Hons.), M.B.A., F.C.A., A.C.M.T.

Executive Director, Macquarie Group Limited;  
Group Treasurer, Macquarie Group Limited

## **Mike Wilson OAM | Director**

Company Secretary and CEO  
Appointed 2011  
B.Sc., B.Ec. (Hons.), G.A.I.C.D.

CEO, JDRF Australia (since 2004)

## **Selina Lightfoot | Director**

Chair of the Talent Committee  
Appointed 2016  
B.A., L.L.B.

Non-Executive Director Hydro Tasmania; Non-Executive Director The Reject Shop; Non-Executive Director Victorian Opera; Non-Executive Director NuChev Pty Ltd; Advisory Board Member TLC Aged Care Pty Ltd; Former Partner Herbert Smith Freehills

## **Professor James Best AO | Director**

Dean, Lee Kong Chian School of Medicine, Singapore (A Joint Medical School by Imperial College London and Nanyang Technological University Singapore); Former Professor of Medicine and Head of the School of Medicine, University of Melbourne; Former Chair of the Research Committee, National Health and Medical Research Council

## **Kate Aitken | Director**

Member of the Talent Committee  
Member of the Finance & Audit Committee  
Appointed 2015

Head of People and Culture Optus; Former General Manager Human Resources Westpac; Former Managing Director, Chief of Staff and Co-COO Goldman Sachs Australia and New Zealand; Advisory Member of Pride in Diversity's Strategic Executive Forum; Member of Chief Executive Women and Scholarship Committee Member; Board Member Bus Stop Films

## **Jeffrey Browne | Director**

Member of the Advisory Board  
Appointed 2015  
B.A., L.L.B.

Chairman and Non-Executive Director, Walkinshaw Automotive Group Pty Ltd, MA Financial Group; Former Chairman and Non-Executive Director of carsales.com Ltd; Former Director Sky News Limited; Former Managing Director and Director Nine Network Australia Pty Ltd; Father of a daughter and son with type 1 diabetes

## **Jonathan Salmon | Director**

Chair of the Funding Committee  
Member of the Research Committee  
Member of the Finance and Audit Committee  
Appointed 2012  
M.A.I.C.D.

Managing Director Adscensio; Chairman Techelevate Director WithWine; Founder DNS IT and Hosted IT; Father of a son with type 1 diabetes

## **Tanya Branwhite | Director / Treasurer**

Chair of the Finance and Audit Committee  
Appointed 2020  
BCom (Hons), Master of Finance, Master of Applied Finance, FAICD

Head of Portfolio Construction, TCorp; Former Director Market Insights and Portfolio Implications, Future Fund; Former Executive Director Macro Research Macquarie Group; Served on the International Accounting Standards Board Capital Market's Advisory Committee (CMAC); Former Director of Not for Profit organisations - MS Research Australia, Oz Harvest, the Anika Foundation and Macquarie Group Foundation.

## **Matthew Rady | Director**

Member of the Funding Committee  
Appointed 2021  
B.Ec, Adelaide

Associate, Institute of Chartered Accountants (Alumni); Fellow; Securities Institute of Australia (Alumni) GAICD; CEO BT Financial Group; Former CEO Allianz Australia Life Insurance Ltd; Former Group Executive, IRESS Ltd; Former Executive Director, Macquarie Group; Prior Director of JDRF Australia 2007-2009

# JDRF Board of Directors cont.

## **Fabienne Mackay | Director**

Member of Research Committee  
Appointed 2021  
PhD, FAHMS

Director and CEO QIMR Berghofer Medical Research Institute; Honorary Professor, Faculty of Medicine University of Queensland; Honorary Professor Faculty of Medicine, Dentistry and Health Sciences University of Melbourne; Member of the QIMR Berghofer Council Faculty of Medicine, Nursing and Health Sciences Monash; Former Head of the Department of Pathology, School of Biomedical Sciences University of Melbourne

## **Ian Narev | Director**

Co-chair of the Advisory Board  
Appointed 2021  
Bachelor of Arts and Law (Honours) from the University of Auckland

Masters of Law from Cambridge University (International Corporate Law) and New York University (International Relations); Managing Director and Chief Executive Officer of SEEK; Former Chief Executive Officer, Commonwealth Bank of Australia; Former partner of McKinsey and Company; Non-profit board roles in education and the performing arts, and advisory board roles in private equity and fintech

# JDRF Advisory Board

## **Richard Goyder AO | Co-Chair**

B.Com., F.A.I.C.D.

Chairman Qantas Airways; Australian Football League Commission; West Australian Symphony Orchestra; Woodside Petroleum Limited & Channel 7 Telethon Trust; Former Managing Director Wesfarmers; Honorary Member of the Business Council of Australia; Father of a son with T1D

## **Ian Narev | Co-Chair**

COO/CEO Asia Pacific & Americas, Seek Ltd  
Former CEO/Managing Director; Commonwealth Bank Chairman; Sydney Theatre Company  
Board Member; Business Council of Australia

## **Andrew Penn**

CEO Telstra; Foundation Board Member of Very Special Kids

## **Phil Chronican**

Chairman NSW Treasury Corporation (TCorp); Chairman National Australia Bank; Non-Executive Director Banking & Finance Oath

## **Rebecca Davies AO**

Former Partner and Board Member of a major national law firm; Member of the Health Innovation Advisory Committee and The Community and Consumer Advisory Group (CCAG) of the National Health and Medical Research Council

## **Professor John Shine AC**

President Academy of Science

## **Steve Higgs OAM**

Chairman GI Foundation; Former Chair JDRF

## **Paul Heath**

Founding Partner and Chief Executive Officer at Koda Capital; Member Endowment Investment Committee of the Benevolent Society; Director JDRF International; Former CEO JBWere Pty Ltd; Father of a daughter with T1D

## **Belinda Hutchinson AM**

Chancellor of the University of Sydney, St Vincent's Health Australia's NSW Advisory Board, Chairman of Thales Australia Limited

## **Simon Rothery**

CEO Goldman Sachs Australia and New Zealand

## **Matthew Grounds**

Former CEO & Country Head Australasia, UBS AG/Australia; Chairman of the Victor Chang Cardiac Research Institute; Member of the University of New South Wales Council; Member of the Business Council of Australia; Director of the UBS Foundation

## **Sir Ralph Norris KNZM**

Former Chairman and Director Contract Energy; Former Chair Fletcher Building; Former CEO Commonwealth Bank

## **Jeffrey Browne**

Chairman and Non-Executive Director Moelis Australia Ltd.; Former Chairman and Non-Executive Director carsales.com Ltd.; Former Director Sky News Limited; Former Managing Director and Director Nine Network Australia Pty Ltd; Father of a daughter and son with T1D

## **Simon McKeon AO**

Chancellor Monash University; Non Executive Director Rio Tinto & National Australia Bank Limited

## **Mark van Dyck**

Regional Managing Director Asia Pacific Compass Group

## **Brian Hartzler**

Former CEO Westpac; Former CEO ANZ Australia

**JDRF** IMPROVING  
LIVES.  
CURING  
TYPE 1  
DIABETES.

 [jdrf.org.au](https://jdrf.org.au)

 [@jdrfaus](https://www.instagram.com/jdrfaus)

 [@jdrfoz](https://www.facebook.com/jdrfoz)

 [@jdrfaus](https://www.twitter.com/jdrfaus)

ABN 40 002 286 553